Camber Capital Management LP

13F Filings History

Latest 13F report
Q2 2025 - Aug 14, 2025
Value $
$718M
Signature - Title
Stephen DuBois - Managing Member
Location
Boston, MA
Summary
This page shows a list of all the recent 13F filings made by Camber Capital Management LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Camber Capital Management LP reported 23 stock holdings with total value $718M as of Q2 2025. Top holdings included ZBH, BAX, HUM, CVS, and GMED.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q2 2025 23 $718M +$135M -$916M -$782M ZBH, BAX, HUM, CVS, GMED 13F-HR 8/14/2025, 04:11 PM
Q1 2025 28 $1.6B +$212M -$1.15B -$938M ZBH, BAX, HUM, CVS, GMED 13F-HR 5/15/2025, 04:17 PM
Q4 2024 36 $2.56B +$600M -$393M +$206M MDT, VTRS, ZBH, HUM, PTCT 13F-HR 2/14/2025, 08:58 AM
Q3 2024 32 $2.57B +$459M -$628M -$170M ZBH, MDT, BAX, VTRS, GMED 13F-HR 11/14/2024, 09:41 AM
Q2 2024 35 $2.59B +$479M -$604M -$125M ZBH, BAX, MDT, UHS, GMED 13F-HR 8/14/2024, 09:28 AM
Q1 2024 33 $2.85B +$314M -$608M -$294M ZBH, UHS, BAX, THC, VTRS 13F-HR 5/15/2024, 08:48 AM
Q4 2023 36 $2.86B +$445M -$623M -$179M UHS, THC, ZBH, VTRS, BAX 13F-HR 2/14/2024, 08:18 AM
Q3 2023 43 $3.03B +$687M -$378M +$309M UHS, PFE, THC, ZBH, VTRS 13F-HR 11/14/2023, 08:56 AM
Q2 2023 43 $3.07B +$271M -$678M -$407M UHS, THC, VTRS, SNY, WBA 13F-HR 8/14/2023, 10:26 AM
Q1 2023 41 $3.25B +$707M -$330M +$378M QQQ, SNY, UHS, THC, WBA 13F-HR 5/15/2023, 09:06 AM
Q4 2022 39 $2.92B +$481M -$316M +$165M SNY, UHS, VTRS, THC, WBA 13F-HR 2/14/2023, 08:01 AM
Q3 2022 45 $3.27B +$1.26B -$201M +$1.06B SNY, VTRS, UHS, SRPT, THC 13F-HR 11/14/2022, 08:37 AM
Q2 2022 40 $2.3B +$476M -$230M +$245M VTRS, SNY, ZBH, SRPT, BMRN 13F-HR 8/15/2022, 08:55 AM
Q1 2022 37 $2.76B +$768M -$249M +$519M VTRS, UHS, SNY, ZBH, GILD 13F-HR 5/16/2022, 08:39 AM
Q4 2021 39 $2.91B +$612M -$460M +$152M VTRS, UHS, MRK, SNY, WBA 13F-HR 2/14/2022, 08:33 AM
Q3 2021 34 $2.69B +$615M -$375M +$240M UHS, WBA, THC, VTRS, SNY 13F-HR 11/15/2021, 09:03 AM
Q2 2021 30 $2.55B +$541M -$678M -$138M THC, WBA, VTRS, HCA, BKD 13F-HR 8/16/2021, 08:52 AM
Q1 2021 31 $2.52B +$595M -$656M -$61.7M CHNG, WBA, UHS, VTRS, THC 13F-HR 5/17/2021, 08:49 AM
Q4 2020 32 $2.85B +$1.1B -$103M +$996M CHNG, VTRS, UHS, ALXN, GILD 13F-HR 2/16/2021, 07:33 AM
Q3 2020 35 $1.9B +$448M -$152M +$295M CHNG, MYL, ALXN, PRGO, UHS 13F-HR/A 11/16/2020, 03:51 PM
Q3 2020 34 $1.9B +$447M -$152M +$295M CHNG, MYL, ALXN, PRGO, UHS 13F-HR 11/16/2020, 07:39 AM
Q2 2020 30 $1.75B +$439M -$194M +$245M CHNG, MYL, ALXN, ALKS, PRGO 13F-HR 8/14/2020, 08:25 AM
Q1 2020 29 $1.67B +$775M -$136M +$639M ALXN, CHNG, MYL, GSKXXXX, UHS 13F-HR 5/15/2020, 08:52 AM
Q4 2019 29 $1.97B +$281M -$204M +$76.4M AGN, MYL, BIIB, GILD, THC 13F-HR 2/14/2020, 08:22 AM
Q3 2019 34 $1.9B +$453M -$152M +$301M AGN, MYL, PRGO, BKD, DVA 13F-HR 11/14/2019, 08:15 AM
Q2 2019 31 $2.15B +$574M -$78.2M +$496M SPY, AGN, MYL, DVA, PRGO 13F-HR 8/14/2019, 09:16 AM
Q1 2019 28 $2.01B +$714M -$193M +$521M SPY, AGN, MYL, PRGO, GBT 13F-HR 5/15/2019, 09:45 AM
Q4 2018 36 $2.11B +$881M -$160M +$721M TSRO, MYL, AGN, AGN, UHS 13F-HR 2/14/2019, 09:17 AM
Q3 2018 26 $2.34B +$550M -$222M +$327M SPY, AGN, HCA, MYL, TSRO 13F-HR 11/14/2018, 08:55 AM
Q2 2018 33 $2.6B +$879M -$215M +$664M SPY, AGN, HCA, BIIB, GHDX 13F-HR 8/14/2018, 09:23 AM
Q1 2018 32 $2.04B +$765M -$284M +$481M SHPG, NKTR, AGN, BIIB, HCA 13F-HR 5/15/2018, 08:48 AM
Q4 2017 34 $2.04B +$646M -$261M +$386M SPY, NKTR, HCA, MYL, AGN 13F-HR 2/14/2018, 09:22 AM
Q3 2017 23 $1.58B +$485M -$236M +$249M SPY, NKTR, THC, MYL, PRGO 13F-HR 11/14/2017, 10:21 AM
Q2 2017 34 $2.05B +$376M -$676M -$300M SPY, TEVA, MYL, GILD, GILD 13F-HR 8/14/2017, 11:18 AM
Q1 2017 32 $2.47B +$924M -$128M +$796M SPY, TEVA, MYL, GILD, NKTR 13F-HR 5/15/2017, 11:17 AM
Q4 2016 35 $1.92B +$678M -$37.3M +$640M TEVA, MYL, SYK, AGN, GILD Restatement 3/16/2017, 09:19 AM
Q3 2016 36 $2.27B +$603M -$110M +$493M SPY, TEVA, MYL, PRGO, GILD 13F-HR 11/14/2016, 10:20 AM
Q2 2016 47 $2.06B +$873M -$159M +$714M SPY, TEVA, MYL, GILD, ENDPQ 13F-HR 8/12/2016, 03:43 PM
Q1 2016 48 $1.71B +$691M +$691M TEVA, MYL, MDCO, BKD, NUVA 13F-HR 5/13/2016, 04:00 PM
Q4 2015 45 $1.55B +$579M -$76.6M +$502M TEVA, SPY, GHDX, MDCO, LIVN 13F-HR 2/12/2016, 07:17 AM
Q3 2015 43 $1.17B +$285M -$66.9M +$219M TEVA, MDCO, AZN, CYBX, MYL 13F-HR 11/13/2015, 09:37 AM
Q2 2015 42 $1.47B +$507M -$190M +$317M TEVA, SPY, AZN, XLV, MASI 13F-HR 8/14/2015, 10:07 AM
Q1 2015 34 $1.39B +$289M -$68.9M +$220M SPY, TEVA, MASI, MDCO, GHDX 13F-HR 5/15/2015, 11:09 AM
Q4 2014 41 $1.5B +$571M -$142M +$429M SPY, TEVA, MASI, GSKXXXX, GHDX Restatement 5/13/2015, 11:50 AM
Q3 2014 37 $1.06B +$389M -$65.2M +$324M TEVA, MYLXXXX, MASI, GHDX, GSKXXXX 13F-HR 11/14/2014, 09:32 AM
Q2 2014 41 $1.53B +$410M -$58.8M +$351M SPY, TEVA, V107SC, DGX, CYH 13F-HR 8/14/2014, 10:03 AM
Q1 2014 39 $1.28B +$550M -$241M +$309M SPY, TEVA, V107SC, THC, DGX 13F-HR 5/15/2014, 10:28 AM
Q4 2013 36 $1.13B TEVA, TEVA, MYLXXXX, V107SC, HCA 13F-HR 2/14/2014, 06:55 AM